Skip to content
akaturk Academic measurement

Academician profile · DOKTOR ÖĞRETİM ÜYESİ

SERCAN ÖN

EGE ÜNİVERSİTESİ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
  • TIP FAKÜLTESİ
  • DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Articles YÖKSİS 16
Projects 1
Books 5
Proceedings 13
Patents 1
Artistic 1
Scopus (SJR)
Q1 5 Q2 1 Q3 3 Q4 4
WoS (JCR)
Q1 3 Q2 3 Q3 2 Q4 4
TR Index 7 articles

Scopus (SJR)

WoS (JCR)

TR Index

7 articles

16 publications total

Articles

  1. 2026 Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group International Journal of Cancer DOI 10.1002/ijc.70213
  2. 2025 Real-World Pathologic Complete Response Rates with Neoadjuvant Pembrolizumab in Stage II–III Triple-Negative Breast Cancer: Impact of Ki-67 Proliferation Index International Journal of Hematology and Oncology DOI 10.4999/uhod.258389
  3. 2025 Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case report Journal of Chemotherapy DOI 10.1080/1120009X.2025.2512262
  4. 2025 Long-term Outcomes in Stage I Seminoma Patients: A Single-center Retrospective Study The Anatolian Journal of General Medical Research DOI 10.4274/anatoljmed.2025.09327
  5. 2025 Tıbbi Onkoloji Polikliniğine Başvuran Yeni Tanı Kanser Hastalarında, Hastalıkları Hakkındaki Bilgi ve Farkındalık Düzeyi The Anatolian journal of general medical research DOI 10.4274/anatoljmed.2024.92905
  6. 2025 Body Mass Index as an Independent Prognostic Factor in Second-Line Nivolumab Therapy for Metastatic Clear Cell Renal Cell Carcinoma Journal of Oncological Sciences DOI 10.37047/jos.galenos.2025.2025-11-10
  7. 2024 Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG) European Archives of Oto-Rhino-Laryngology DOI 10.1007/s00405-024-08744-4
  8. 2024 Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study Current Oncology DOI 10.3390/curroncol31110502
  9. 2024 Radiotherapy can be a Cofactor in the Development and Severity of Lapatinib-Capecitabine-Related Skin Rash Asthma Allergy Immunology DOI 10.21911/aai.247
  10. 2023 Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group The Oncologist DOI 10.1093/oncolo/oyad257
  11. 2023 PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study Journal of Geriatric Oncology DOI 10.1016/j.jgo.2023.101604
  12. 2023 Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye Eurasian Journal of Medicine and Oncology DOI 10.14744/ejmo.2023.48337
  13. 2022 Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study BREAST DOI 10.1016/j.breast.2022.09.009
  14. 2022 Immunotherapy-induced granulomatous reaction in patients with melanoma Melanoma Research DOI 10.1097/cmr.0000000000000815
  15. 2022 Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group JOURNAL OF CANCER RESEARCH AND THERAPEUTICS DOI 10.4103/jcrt.jcrt_1104_21
  16. 2022 Evaluation of treatment efficacy of tyrosine kinase inhibitors in rare single EGFR Exon 21 L861Q mutation: Single center experience Turkish Thoracic Journal DOI 10.5152/TurkThoracJ.2022.21270

Back to academicians